Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • IkT-148009 for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Mar 23, 2023 5:15pm EDT

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

Mar 21, 2023 8:00am EDT

Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

Mar 16, 2023 8:30am EDT

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

Mar 15, 2023 8:35am EDT

Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro

Mar 08, 2023 8:30am EST

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy

Feb 15, 2023 4:05pm EST

Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit

Jan 27, 2023 4:05pm EST

Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules

Jan 25, 2023 1:00pm EST

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules

Jan 25, 2023 8:35am EST

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders

Jan 25, 2023 8:05am EST

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap